223 related articles for article (PubMed ID: 25904247)
21. Alternative splicing of the histone demethylase LSD1/KDM1 contributes to the modulation of neurite morphogenesis in the mammalian nervous system.
Zibetti C; Adamo A; Binda C; Forneris F; Toffolo E; Verpelli C; Ginelli E; Mattevi A; Sala C; Battaglioli E
J Neurosci; 2010 Feb; 30(7):2521-32. PubMed ID: 20164337
[TBL] [Abstract][Full Text] [Related]
22. Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation.
Zhang YL; Sun JW; Xie YY; Zhou Y; Liu P; Song JC; Xu CH; Wang L; Liu D; Xu AN; Chen Z; Chen SJ; Sun XJ; Huang QH
Cell Res; 2018 Apr; 28(4):476-490. PubMed ID: 29531312
[TBL] [Abstract][Full Text] [Related]
23. Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis.
Pronier E; Bowman RL; Ahn J; Glass J; Kandoth C; Merlinsky TR; Whitfield JT; Durham BH; Gruet A; Hanasoge Somasundara AV; Rampal R; Melnick A; Koche RP; Taylor BS; Levine RL
Blood; 2018 Sep; 132(12):1265-1278. PubMed ID: 30064973
[TBL] [Abstract][Full Text] [Related]
24. Histone demethylase LSD1-mediated repression of GATA-2 is critical for erythroid differentiation.
Guo Y; Fu X; Jin Y; Sun J; Liu Y; Huo B; Li X; Hu X
Drug Des Devel Ther; 2015; 9():3153-62. PubMed ID: 26124638
[TBL] [Abstract][Full Text] [Related]
25. Low-level GATA2 overexpression promotes myeloid progenitor self-renewal and blocks lymphoid differentiation in mice.
Nandakumar SK; Johnson K; Throm SL; Pestina TI; Neale G; Persons DA
Exp Hematol; 2015 Jul; 43(7):565-77.e1-10. PubMed ID: 25907033
[TBL] [Abstract][Full Text] [Related]
26. The histone demethylase Lsd1 regulates multiple repressive gene programs during T cell development.
Stamos DB; Clubb LM; Mitra A; Chopp LB; Nie J; Ding Y; Das A; Venkataganesh H; Lee J; El-Khoury D; Li L; Bhandoola A; Bosselut R; Love PE
J Exp Med; 2021 Dec; 218(12):. PubMed ID: 34726730
[TBL] [Abstract][Full Text] [Related]
27. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells.
Zheng X; Beissert T; Kukoc-Zivojnov N; Puccetti E; Altschmied J; Strolz C; Boehrer S; Gul H; Schneider O; Ottmann OG; Hoelzer D; Henschler R; Ruthardt M
Blood; 2004 May; 103(9):3535-43. PubMed ID: 14739224
[TBL] [Abstract][Full Text] [Related]
28. The Pluripotency Regulator PRDM14 Requires Hematopoietic Regulator CBFA2T3 to Initiate Leukemia in Mice.
Tracey LJ; Brooke-Bisschop T; Jansen PWTC; Campos EI; Vermeulen M; Justice MJ
Mol Cancer Res; 2019 Jul; 17(7):1468-1479. PubMed ID: 31015254
[TBL] [Abstract][Full Text] [Related]
29. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
30. Silencing of LSD1 gene modulates histone methylation and acetylation and induces the apoptosis of JeKo-1 and MOLT-4 cells.
Zou ZK; Huang YQ; Zou Y; Zheng XK; Ma XD
Int J Mol Med; 2017 Aug; 40(2):319-328. PubMed ID: 28627608
[TBL] [Abstract][Full Text] [Related]
31. Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis.
Wang Z; Medrzycki M; Bunting ST; Bunting KD
Oncotarget; 2015 Oct; 6(30):28961-72. PubMed ID: 26338970
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
[TBL] [Abstract][Full Text] [Related]
33. T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development.
de Bock CE; Down M; Baidya K; Sweron B; Boyd AW; Fiers M; Burns GF; Molloy TJ; Lock RB; Soulier J; Taghon T; Van Vlierberghe P; Cools J; Holst J; Thorne RF
Haematologica; 2019 May; 104(5):e204-e207. PubMed ID: 30514801
[No Abstract] [Full Text] [Related]
34. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic dysregulation of ZEB1 is involved in LMO2-promoted T-cell acute lymphoblastic leukaemia leukaemogenesis.
Wu C; Li J; Tian C; Shi W; Jiang H; Zhang Z; Wang H; Zhang Q; Sun W; Sun P; Xiang R; Yang S
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2511-2525. PubMed ID: 29778661
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylation of neuronal Lysine-Specific Demethylase 1LSD1/KDM1A impairs transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2.
Toffolo E; Rusconi F; Paganini L; Tortorici M; Pilotto S; Heise C; Verpelli C; Tedeschi G; Maffioli E; Sala C; Mattevi A; Battaglioli E
J Neurochem; 2014 Mar; 128(5):603-16. PubMed ID: 24111946
[TBL] [Abstract][Full Text] [Related]
37. Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch.
Tu WJ; McCuaig RD; Tan AHY; Hardy K; Seddiki N; Ali S; Dahlstrom JE; Bean EG; Dunn J; Forwood J; Tsimbalyuk S; Smith K; Yip D; Malik L; Prasanna T; Milburn P; Rao S
Front Immunol; 2020; 11():1228. PubMed ID: 32612611
[TBL] [Abstract][Full Text] [Related]
38. Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171.
Subramaniam A; Žemaitis K; Talkhoncheh MS; Yudovich D; Bäckström A; Debnath S; Chen J; Jain MV; Galeev R; Gaetani M; Zubarev RA; Larsson J
Blood; 2020 Nov; 136(19):2151-2161. PubMed ID: 32582923
[TBL] [Abstract][Full Text] [Related]
39. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia.
Van der Meulen J; Sanghvi V; Mavrakis K; Durinck K; Fang F; Matthijssens F; Rondou P; Rosen M; Pieters T; Vandenberghe P; Delabesse E; Lammens T; De Moerloose B; Menten B; Van Roy N; Verhasselt B; Poppe B; Benoit Y; Taghon T; Melnick AM; Speleman F; Wendel HG; Van Vlierberghe P
Blood; 2015 Jan; 125(1):13-21. PubMed ID: 25320243
[TBL] [Abstract][Full Text] [Related]
40. Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date.
Mould DP; McGonagle AE; Wiseman DH; Williams EL; Jordan AM
Med Res Rev; 2015 May; 35(3):586-618. PubMed ID: 25418875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
